Precision Medicine: Key Updates for Treatment of NSCLC

EP. 1: ADAURA Trial; Early Stage Non–Small Cell Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

EP. 2: Role of Adjuvant Osimertinib in Early Stage NSCLC

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

EP. 3: TKI Combinations in Metastatic EGFR+ Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

EP. 4: Chemotherapy-TKI Combinations in Metastatic EGFR+ Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

EP. 5: EGFR Exon 20 Mutations in Non–Small Cell Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

EP. 6: Treating Non–Small Cell Lung Cancer With an EGFR Exon 20 Insertion

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

EP. 7: Trastuzumab Deruxtecan for HER2+ Non–Small Cell Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

EP. 8: KRAS Testing in Non¬–Small Cell Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

EP. 9: Trials in ALK-Rearranged Non–Small Cell Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

EP. 10: Treating ALK-Rearranged Non–Small Cell Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

EP. 11: Rebiopsy at Progression of ALK-Rearranged NSCLC

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

EP. 12: ROS1-Rearranged Non–Small Cell Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

EP. 13: RET Fusions in Non–Small Cell Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

EP. 14: MET Exon 14 Mutations in Non–Small Cell Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

EP. 15: NTRK Fusions in Non–Small Cell Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

EP. 16: Optimizing Testing Strategies in Non–Small Cell Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

EP. 1: ADAURA Trial; Early Stage Non–Small Cell Lung Cancer

EP. 2: Role of Adjuvant Osimertinib in Early Stage NSCLC

EP. 3: TKI Combinations in Metastatic EGFR+ Lung Cancer

EP. 4: Chemotherapy-TKI Combinations in Metastatic EGFR+ Lung Cancer

EP. 5: EGFR Exon 20 Mutations in Non–Small Cell Lung Cancer

EP. 6: Treating Non–Small Cell Lung Cancer With an EGFR Exon 20 Insertion

EP. 7: Trastuzumab Deruxtecan for HER2+ Non–Small Cell Lung Cancer

EP. 8: KRAS Testing in Non¬–Small Cell Lung Cancer

EP. 9: Trials in ALK-Rearranged Non–Small Cell Lung Cancer

EP. 10: Treating ALK-Rearranged Non–Small Cell Lung Cancer

EP. 11: Rebiopsy at Progression of ALK-Rearranged NSCLC

EP. 12: ROS1-Rearranged Non–Small Cell Lung Cancer

EP. 13: RET Fusions in Non–Small Cell Lung Cancer

EP. 14: MET Exon 14 Mutations in Non–Small Cell Lung Cancer

EP. 15: NTRK Fusions in Non–Small Cell Lung Cancer

EP. 16: Optimizing Testing Strategies in Non–Small Cell Lung Cancer

Trending on OncLive

ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC

Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL

Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC

Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg

HERTHENA-Breast04 Is Set to Delineate the Role of HER3-Targeted Therapy in Advanced HR+ Breast Cancer